What are the key entities being sold by WellPoint?

WellPoint is selling its indirect, wholly-owned subsidiaries: Community Insurance Company's interest in NextRx, LLC; UNICARE Specialty Services, Inc.'s stock in NextRx Services, Inc.; and UNICARE Specialty Services, Inc.'s stock in NextRx, Inc. Collectively, these are referred to as the 'Sold Entities.'

What is the total value of the transaction and how is it structured?

The total transaction value is $4.675 billion. This is comprised of $3.275 billion in cash, subject to customary working capital and indebtedness adjustments, and $1.400 billion in shares of Express Scripts common stock.

What are the main conditions that need to be met for the sale to close?

The sale is subject to several conditions, including the absence of any legal or governmental prohibitions, receipt of U.S. antitrust and other required regulatory approvals without burdensome conditions, accuracy of representations and warranties, material compliance with covenants, financial condition of the sold entities not being materially worse than previously disclosed, and completion of certain system build-outs by December 31, 2009.

Will WellPoint still have a relationship with Express Scripts after the sale?

Yes, upon closing, WellPoint and Express Scripts will enter into a 10-year pharmacy benefits management contract, under which Express Scripts will provide PBM services to WellPoint. Additionally, a transition services agreement will facilitate the handover of operations.

ELV 8-K: Material Agreements

Summary

Elevance Health, Inc. (then known as WellPoint, Inc.) filed an 8-K on April 13, 2009, to announce a significant divestiture. The company entered into a Stock and Interest Purchase Agreement with Express Scripts, Inc. to sell its pharmacy benefit management (PBM) operations, collectively referred to as the 'Sold Entities' (NextRx, LLC, NextRx Services, Inc., and NextRx, Inc.). This transaction represents a strategic shift for WellPoint, moving away from direct PBM services to focus on its core health insurance business. The sale is valued at an aggregate of $4.675 billion, comprised of $3.275 billion in cash (subject to adjustments) and $1.400 billion in Express Scripts common stock. The agreement includes customary representations, warranties, and covenants, with no financing condition for Express Scripts. The deal is subject to regulatory approvals, including antitrust clearance, and other closing conditions. Post-closing, WellPoint will enter into a 10-year PBM contract with Express Scripts for services and a transition services agreement. Investors should note the substantial cash and stock proceeds, the strategic implications of exiting the PBM business, and the ongoing PBM services relationship.

Key Highlights

1WellPoint, Inc. (now Elevance Health) is divesting its pharmacy benefit management (PBM) subsidiary, NextRx and related entities, to Express Scripts, Inc.
2The total transaction value is $4.675 billion, consisting of $3.275 billion in cash and $1.400 billion in Express Scripts common stock.
3The agreement is not subject to a financing condition for Express Scripts, indicating a strong commitment to the deal.
4Consummation of the sale is contingent upon customary closing conditions, including regulatory and antitrust approvals.
5Following the sale, WellPoint will enter into a 10-year pharmacy benefit management services agreement with Express Scripts.
6A transition services agreement will be in place for WellPoint to temporarily provide IT and related services to Express Scripts post-closing.

Elevance Health, Inc. 8-K Report, Material Agreement (Apr 13, 2009)

Summary

Key Highlights

Frequently Asked Questions